Nextage Therapeutics (TASE: NXTG) is a pioneer in targeted nano-liposomes based drug delivery across the blood-brain-barrier. The company has developed a proprietary BTLs drug delivery platform which is being studied for various therapeutic applications, and its lead drug candidate is currently under development for treatment of glioblastoma. Through its subsidiary Nextar Chempharma Solutions, Israel's leading CDMO with 20 years cGMP and ISO 13485 compliant track record, the company also provides development and commercial manufacturing services for pharmaceuticals and medical devices across a broad range of technologies and dosage forms including drug substance synthesis, formulation development, scale up and sterile manufacturing, from preclinical development through clinical trials and commercial supply.